Navigation Links
Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting

PHILADELPHIA May 1, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments, said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options.

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:
May 7, 2008; 12:00 p.m. ET
Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD: Parental Impressions and Experiences
APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD
APA Oral Presentation Session # 28

Methylphenidate Transdermal System:
May 7, 2008; 12:00 p.m. ET
Long-Term Treatment Effects of the Methylphenidate Transdermal System in Boys and Girls with ADHD
APA Poster Presentation # NR6-018

Guanfacine Extended Release:
May 7, 2008; 12:00 p.m. ET
Guanfacine Extended Release: Duration of Effect in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-008

May 7, 2008; 12:00 p.m. ET
Response to Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-040


Contact: Lucia Lodato
Porter Novelli

Related medicine news :

1. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
2. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
3. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
4. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Families Invited to Celebrate Shire Day at Boston Childrens Museum
8. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
9. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
10. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... PUNE, India , November 30, ... --> --> ... deal trends for 2010 - 2015 ... activity for a range of deal ... (M&A) and strategic alliances. ...
(Date:11/30/2015)... Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices ... systems, and PTS Detect™ cotinine systems, has announced the ... the company into the mHealth market. ... The technology is a system that interfaces with mobile ... and uses test strip technology already developed by PTS ...
Breaking Medicine Technology: